학술논문
High target binding affinity with long lasting cellular target engagement and high dose intermittent schedule of PI3K inhibitor copanlisib contribute to the potent anti-tumor activity and good safety profile
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445